249 results found

It is now over a year since regulations came into force effectively putting an end to pension scheme trustees borrowing money directly.

The Court of Appeal in Glaxo v Genentech [2008] EWCA Civ 23 has clarified the test on whether to stay UK proceedings for revocation of a UK designation of a European patent pending resolution of opposition proceedings to the patent at the European Patent Office (EPO).

Both Nominet and WIPO have recently upheld complaints by footballer Wayne Rooney and Stoneygate 48 Limited, a company wholly owned by him, against the registration of the domain names waynerooney.co.uk and waynerooney.com (respectively), and ordered the transfer of the domain names to Stoneygate (which owns all the intellectual property rights in the Wayne Rooney name and image).

Expanding into the UK market requires careful navigation of data protection regulations that extend beyond the GDPR. This podcast episode explores essential UK privacy considerations, from the UK GDPR and Data Protection Act 2018 to cookies and electronic marketing requirements that overseas businesses must understand when establishing operations in the UK.

First of all, what is cloud computing? At its simplest, it is an arrangement whereby IT resources are provided as a service via the Internet, typically on demand and often without reference to geography or specific local infrastructure.

Sharp on the heels of its review of its rules on vertical agreements (see here), the European Commission has also announced its intention to revise its rules and guidance...

We have previously written at length about the continuing regulatory bottlenecks caused by the low numbers of notified bodies for the EU's Medical Device Regulation and In Vitro Diagnostic Medical Devices Regulation.

This month's CLIP is a blog post by Adrian Deuschle covering a decision by the German Federal Supreme Court (Bundesgerichtshof) that found the narrow MFN clauses in Booking.com BV's terms and conditions incompatible with Art 101 TFEU.

In the fourth episode of our podcast series on patent settlement agreements and competition law, Edwin Bond introduces the concept of restrictions of competition ‘by object' under Art 101 TFEU.

The Companies Act 2006 sees the introduction of many new rules relating to directors. One of the most welcome, from the perspective of those considering taking on a directorship in a company in the life sciences sphere, is a new provision that permits directors to have the option of filing a service address on the public record with the Registrar of Companies, rather than their private home address.

Marc Dautlich and Alex Denoon explore the complexities of the EU AI Act's Declaration of Conformity requirements, specifically examining what it means for High-Risk AI Systems to comply with GDPR. The podcast addresses the practical challenges providers face when preparing this living document for AI-integrated medical devices and other regulated systems.

Notified body capacity – or a lack thereof – is a topic we love to keep you updated on here at OTP.

Pharmaceutical law expert Julian Hitchcock spoke to Nature about gene editing regulation and the recent WHO's Committee's recommendations (read Julians initial thoughts here).

To much fanfare, but a dearth of detail, Theresa May announced on 2 October that the Government will introduce a ‘Great Repeal Bill' in the next Queen's Speech.

Widespread use of email and increasingly advanced mobile phones has created wider opportunities for advertising. However, unsolicited email and texts are often unwelcome and put customers off, rather than encouraging them to buy.

Further to our earlier blog posts on the New Competition Tool and the Digital Markets Unit, this month's CLIP is an OECD discussion paper authored by Chris Pike and Antonio Capobianco, on competition

The European Commission recently released its draft revised Vertical Block Exemption Regulation (VBER) and Vertical Guidelines.

Under the terms of the Northern Ireland Protocol, different rules apply in Northern Ireland and the rest of the UK when placing medical devices on the market.